ESTROGENS, ESTRONE (E1) AND ESTRADIOL (E2), FRACTIONATED
General Information
HLAB/HOL Code: ESTF
UPHSM LIS Test #: 026578
Schedule:
Testing Time: 2-4 Days
Testing Lab: Mayo
UPHSM LIS Test #: 026578
Schedule:
Testing Time: 2-4 Days
Testing Lab: Mayo
Specimen Info
Only 1 specimen type required, unless otherwise specified
Volume: 1.2 mL
Temperature: Refrigerate
Tube Type: Serum
Collection Info:
Collection Container/Tube: Red top (Serum gel/SST is NOT acceptable)
Submission Container/Tube: Plastic vial
Collection Instructions: Centrifuge and aliquot serum in plastic vial within 2 hours of collection.
Temperature: Refrigerate
Tube Type: Serum
Collection Info:
Collection Container/Tube: Red top (Serum gel/SST is NOT acceptable)
Submission Container/Tube: Plastic vial
Collection Instructions: Centrifuge and aliquot serum in plastic vial within 2 hours of collection.
Specimen Acceptability
REJECT DUE TO:
Gross hemolysis: OK
Gross lipemia: OK
Gross icterus: OK
Gross hemolysis: OK
Gross lipemia: OK
Gross icterus: OK
Methods
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Clinical Utilities
Simultaneous high-sensitivity determination of serum estrone and estradiol levels
Situations requiring either higher sensitivity estradiol measurement, estrone measurement, or both, including
-As part of the diagnosis and workup of precocious and delayed puberty in females and, to a lesser degree, males
-As part of the diagnosis and workup of suspected disorders of sex steroid metabolism, eg, aromatase deficiency and 17 alpha-hydroxylase deficiency
-As an adjunct to clinical assessment, imaging studies, and bone mineral density measurement in the fracture risk assessment of postmenopausal women and, to a lesser degree, older men
-Monitoring low-dose female hormone replacement therapy in postmenopausal women
-Monitoring antiestrogen therapy (eg, aromatase inhibitor therapy)
Applications that require moderately sensitive measurement of estradiol including:
-Evaluation of hypogonadism and oligo-amenorrhea in females
-Assessing ovarian status, including follicle development, for assisted reproduction protocols (eg, in vitro fertilization)
In conjunction with luteinizing hormone measurements, monitoring of estrogen replacement therapy in hypogonadal premenopausal women
Evaluation of feminization, including gynecomastia, in males
Diagnosis of estrogen-producing neoplasms in males, and, to a lesser degree, females
Situations requiring either higher sensitivity estradiol measurement, estrone measurement, or both, including
-As part of the diagnosis and workup of precocious and delayed puberty in females and, to a lesser degree, males
-As part of the diagnosis and workup of suspected disorders of sex steroid metabolism, eg, aromatase deficiency and 17 alpha-hydroxylase deficiency
-As an adjunct to clinical assessment, imaging studies, and bone mineral density measurement in the fracture risk assessment of postmenopausal women and, to a lesser degree, older men
-Monitoring low-dose female hormone replacement therapy in postmenopausal women
-Monitoring antiestrogen therapy (eg, aromatase inhibitor therapy)
Applications that require moderately sensitive measurement of estradiol including:
-Evaluation of hypogonadism and oligo-amenorrhea in females
-Assessing ovarian status, including follicle development, for assisted reproduction protocols (eg, in vitro fertilization)
In conjunction with luteinizing hormone measurements, monitoring of estrogen replacement therapy in hypogonadal premenopausal women
Evaluation of feminization, including gynecomastia, in males
Diagnosis of estrogen-producing neoplasms in males, and, to a lesser degree, females
CPT Codes
82670-Estradiol
82679-Estrone
When performed together as test ESTF:
82671 Estrogens, fractionated
82679-Estrone
When performed together as test ESTF:
82671 Estrogens, fractionated
* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding
is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Reference Range
See Report
